Cingulate partners with Indegene for ADHD therapy
Pharmaceutical Technology
MARCH 14, 2023
Biopharmaceutical firm Cingulate and life sciences commercialisation firm Indegene have entered into a joint commercialisation deal for the former’s attention-deficit/hyperactivity disorder (ADHD) therapy CTx-1301 (dexmethylphenidate).
Let's personalize your content